2.65 USD
+0.07 (+2.71%)
We assign a fundamental rating of 5 out of 10 to BTMD. BTMD was compared to 190 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on BTMD.
1. Profitability
1.1 Basic Checks
In the past year BTMD was profitable.
In the past year BTMD had a positive cash flow from operations.
Of the past 5 years BTMD 4 years were profitable.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 25.87%, BTMD belongs to the top of the industry, outperforming 98.42% of the companies in the same industry.
BTMD has a better Return On Invested Capital (45.22%) than 99.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 14.72%, BTMD belongs to the best of the industry, outperforming 86.84% of the companies in the same industry.
BTMD's Profit Margin has declined in the last couple of years.
BTMD's Operating Margin of 16.09% is amongst the best of the industry. BTMD outperforms 85.79% of its industry peers.
In the last couple of years the Operating Margin of BTMD has declined.
The Gross Margin of BTMD (72.23%) is better than 78.95% of its industry peers.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.28 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD has a better Altman-Z score (2.28) than 61.05% of its industry peers.
BTMD has a debt to FCF ratio of 4.18. This is a neutral value as BTMD would need 4.18 years to pay back of all of its debts.
The Debt to FCF ratio of BTMD (4.18) is better than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.28 |
ROIC/WACC4.84
WACC9.34%
2.3 Liquidity
A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.01, BTMD is doing worse than 84.74% of the companies in the same industry.
BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.72, BTMD is not doing good in the industry: 85.26% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 190.00% over the past year.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.53% yearly.
Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -18.44% in the last year.
Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
The Revenue is expected to grow by 6.89% on average over the next years.
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 3.05, the valuation of BTMD can be described as very cheap.
Based on the Price/Earnings ratio, BTMD is valued cheaper than 97.37% of the companies in the same industry.
When comparing the Price/Earnings ratio of BTMD to the average of the S&P500 Index (27.19), we can say BTMD is valued rather cheaply.
A Price/Forward Earnings ratio of 10.12 indicates a reasonable valuation of BTMD.
88.42% of the companies in the same industry are more expensive than BTMD, based on the Price/Forward Earnings ratio.
BTMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.05 | ||
| Fwd PE | 10.12 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 95.26% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 98.95% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.52 | ||
| EV/EBITDA | 6.61 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y9.09%
EPS Next 3Y9.09%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BTMD (1/12/2026, 10:16:30 AM)
2.65
+0.07 (+2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners63.14%
Inst Owner Change-0.53%
Ins Owners10.06%
Ins Owner Change0%
Market Cap121.00M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target5.2 (96.23%)
Short Float %3.9%
Short Ratio8.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.77%
EPS NY rev (1m)0%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.05 | ||
| Fwd PE | 10.12 | ||
| P/S | 0.62 | ||
| P/FCF | 3.52 | ||
| P/OCF | 3.03 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.61 |
EPS(TTM)0.87
EY32.83%
EPS(NY)0.26
Fwd EY9.88%
FCF(TTM)0.75
FCFY28.44%
OCF(TTM)0.88
OCFY33.05%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.28 |
F-Score7
WACC9.34%
ROIC/WACC4.84
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
Can you provide the valuation status for BIOTE CORP -A?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
How financially healthy is BIOTE CORP -A?
The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.
How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.